Kornimate/medical-research-clean huggingface dataset:
galectin-3 in papillary thyroid carcinoma

Conditions: Galactin 3-thyroid Carcinoma

Summary: thyroid cancer is a common head and neck malignancy. it is the most common endocrine tumor in the body accounting for 1% of all cancers worldwide. the incidence of thyroid cancer varies worldwide. most countries have reported an upward trend in its incidence. thyroid cancer encompass the most common well-differentiated papillary carcinoma (80% of all thyroid cancers) and follicular carcinoma (15%), as well as poorly differentiated carcinoma (\< 1%) and anaplastic carcinoma (\< 2%). papillary thyroid carcinomas (ptcs) are the most commonly encountered thyroid malignancies. the diagnosis of ptc is based on the special nuclear features such as overlapping of nuclei, intranuclear inclusions, optical clearing, anisonucleosis and nuclear grooves. however, it is often difficult to differentiate ptc from benign papillary thyroid hyperplasia . as differentiation between benign or malignant thyroid lesions has clinical, therapeutic, and prognostic significance, it is necessary to make accurate diagnosis by using biomarkers. recently, a large number of immunohistochemical (ihc) markers have been studied to assist in differentiating non-neoplastic lesions from malignant thyroid lesions. ck19, galectin-3, tg, ki67, braf, calcitonin, hbme-1, ttf-1, and ret are some of the examples of these ihc markers. galectin-3 is a 31-kda β-galactoside binding lectin. it has been shown to be expressed by several types of non-neoplastic and neoplastic cells, and it is involved in cell-cell adhesion and in cell-matrix interactions.


Eligibility criteria:
inclusion criteria: 1. thyroidectomy specimens both hemithyroidectomy and total thyroidectomy. 2. all the studied cases include sufficient materials for the immunohistochemical study. 3. complete clinical data exclusion criteria: 1. patients with recurrence of the primary tumor. 2. patients with a history of preoperative chemotherapy and/or radiotherapy. 3. insufficient or tiny tissue biopsies
clinical evaluation of nx-1207 for the treatment of benign prostatic hyperplasia (bph) nx02-0018

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: this study will evaluate the safety and efficacy of a 2.5 mg dose of nx-1207 for the treatment of bph (benign prostatic hyperplasia) as compared to placebo.


Eligibility criteria:
inclusion criteria: 1. provide signed informed consent prior to enrolment in the study 2. auasi ≥ 15 3. prostate volume ≥ 30 ml ≤ 70 ml 4. qmax \< 15 ml/sec based on a minimum void of 125 ml 5. agree not to use any other approved or experimental bph or oab medication anytime during the study exclusion criteria: 1. history of illness or condition that may interfere with study or endanger subject 2. use of prescribed medications that may interfere with study or endanger subject 3. presence of a median lobe of the prostate 4. previous surgery or mist for treatment of bph 5. post-void residual urine volume \> 200 ml 6. psa ≥ 10 ng/ml; prostate cancer must be ruled out (negative biopsy) for psa ≥ 4 ng/ml 7. participation in a study of any investigational drug or device within the previous 90 days 8. prostate cancer

Keywords: benign prostatic hyperplasia bph enlarged prostate
the efficacy and safety of fruquintinib plus folfiri/folfox as second-line treatment in patients with ras-mutant metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: ras mutations are found in nearly half of colorectal cancer patients. however, there is no targeted driver gene drugs have been approved for ras-mutated patients. for ras mutant metastatic colorectal cancer, the commonly used treatment regimen is bevacizumab combined with chemotherapy.

this is a single-center, open, single-arm study exploring the efficacy and safety of fruquintinib combined with folfiri/folfox in the treatment of ras-mutated metastatic colorectal cancer (mcrc) who failed standard therapy. patients will receive fruquinitinib combined with chemotherapy (folfox or folfiri regimens), which depend on the previous chemotherapy regimen (chemotherapy switch).

Eligibility criteria:
inclusion criteria: * ≥18 years * histological or cytological confirmed colorectal cancer; * ras mutation * expected survival \>12 weeks; * fail in previous standard therapy, which must include folfox/folfiri; * ecog ps 0-1; * at least one measurable lesion (according to recist1.1); * adequate hepatic, renal, heart, and hematologic functions; * negative serum pregnancy test at screening for women of childbearing potential. exclusion criteria: * received other investigational drugs within 4 weeks prior to treatment; * prior treatment with anti-angiogenic small molecule targeted drugs, such as fruquintinib, etc; * symptomatic brain or meningeal metastases (except for patients with bms who have received local radiotherapy or surgery for more than 6 months and whose disease is stable); * severe infection (e.g., requiring intravenous antibiotics, antifungal drugs, or antiviral drugs) within 4 weeks prior to treatment; * patients with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥140 mmhg or diastolic blood pressure ≥90 mmhg); * patients who had active bleeding or coagulopathy within 2 months before enrollment, had a tendency to bleed, or were receiving thrombolytic therapy and were considered by the investigator to be ineligible for enrollment; * active heart disease, including myocardial infarction, severe/unstable angina, 6 months prior to treatment. echocardiography examination left ventricular ejection fraction \< 50%, arrhythmia control is not good; * the patient has had other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); * allergy to the study drug or any of its excipients; * the patient is unable to take the drug orally, or the patient has a condition judged by the investigator to affect the absorption of the drug; * women who are pregnant (with a positive pregnancy test before medication) or breastfeeding; * urine routine showed urine protein ≥2+, and 24-hour urine protein level \>1.0g; * other conditions deemed by the investigator to be ineligible for inclusion in the study.

Keywords: fruquintinib plus chemotherapy ras mutation
study of abt-869 in subjects with advanced non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Summary: the purpose of this study is to evaluate the effect of the abt-869 on the nsclc subjects.


Eligibility criteria:
inclusion criteria: * subject must be histologically or cytologically diagnosed with advanced or metastatic nsclc * subjects must have at least one lesion measurable by ct scan as defined by recist * the measurable lesion may have not received radiation therapy * subject has an eastern cooperative oncology group (ecog) performance status of 0-2 * subject has received at least one prior line of systemic treatment but no more than two treatment regimen(s) for advanced or metastatic nsclc. in addition, the subject may have received systemic neo-adjuvant or adjuvant chemotherapy for nsclc * adequate organ function exclusion criteria: * subject has received targeted vegf/pdgf tki (tyrosine kinase inhibitor) therapy. prior avastin is allowed. * subject has untreated brain or meningeal metastases. * history of greater than 10% weight loss * subject has clinically relevant hemoptysis * the subject has proteinuria ctc grade \> 1 * the subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure \> 100 mmhg or systolic blood pressure \> 150 mmhg. subjects may be re-screened if blood pressure is shown to be controlled with or without intervention. * the subject has a documented left ventricular ejection fraction \< 50%

Keywords: refractory metastatic
immersive virtual reality for dual-task training in older adults with mild cognitive impairment: a randomized controlled trial

Conditions: Mild Cognitive Impairment

Summary: mild cognitive impairment (mci) is a pre-dementia state marked by a higher risk of conversion to dementia. presently, strategies to delay the progression of mci to dementia, such as routine exercise and cognitive activities, are limited and only moderately efficacious. cognitive-motor dual task training, enhanced in a virtual reality environment, is a novel intervention for individuals with mci.

a randomized controlled trial will be conducted. 54 patients with mci will be recruited from an outpatient clinic. the participants will be randomly allocated to one of the three study arms. all three groups will participate in 2 training sessions per week for 7 weeks. each session lasts 32 to 40 minutes.

Eligibility criteria:
inclusion criteria: * age 60 - 80 years of age * diagnosis of mild cognitive impairment (mci) * able to walk independently without assistance, whether from a person or a walking aid exclusion criteria: * diagnosed dementia (at the point of recruitment) * presence of end stage lung, cardiac, liver and/or renal disease * unstable acute medical conditions that prevent one from exercising on a treadmill * presence of active arthritis, with symptoms affecting function * cerebrovascular and/or cardiac events in the last 6 months * parkinson's disease * history of hip fracture within the last 6 months * history of epilepsy with seizures in the last 2 years * poor vision, not correctable by glasses * hearing difficulty (if unable to hear well at normal conversational volume) * acute backache with pain affecting ambulation * acute lower limb pain with pain affecting ambulation * cervical spondylosis with myelopathy or cervical spine issues * chronic vertigo * vestibular problems, causing issues with balance
pharmacodynamics of mitiglinide/sitagliptin compared to mitiglinide and sitagliptin

Conditions: Type 2 Diabetes Mellitus

Summary: 1. explore pharmacodynamics * glucose * insulin * c-peptide * glucagon * intact glp-1 * dpp-4 activity * cgms (continuous glucose monitoring system) 2. assess safety * adverse events * clinical laboratory test * physical examination

pharmacodynamic assessment * cgms data is obtained from day 1 to day 3 (48 hours) * pd is measured before (day 1) and after drug administration (day 2) 1. auc of glucose, insulin, c-peptide, glucagon, intact glp-1, dpp-4 activity 2. mage (mean amplitude of glycemic excursion) from cgms data

Eligibility criteria:
inclusion criteria: * male or female patients with type 2 diabetes mellitus * 6.5% ≤ hba1c \< 9.0% * stopped treatment of sulfonylurea and biguanide for more than 8 weeks * stopped treatment of other anti-diabetic agents for more than 12 weeks * 16 kg/m2 ≤ body mass index \< 30 kg/m2 exclusion criteria: * fasting glucose ≥ 200 mg/dl * required insulin therapy * patients with neuropathy, retinopathy or renopathy * contraindicated for mitiglinide or sitagliptin

Keywords: sitagliptin mitiglinide type 2 diabetes mellitus pharmacodynamics safety
effects of transcranial direct current stimulation on glucose level

Conditions: Glucose Metabolism Disorders

Summary: previous studies have investigated the impact of tdcs on systemic glucose, neglecting to explore its effects on diabetic factors and its safety. some studies used small sample size, limiting the ability to identify significant impacts or generalized findings to large population.

the proposed study suggests addressing these gaps by employing a large sample size, comprehensive outcome measurements, assessing tdcs impact on diabetes mellitus (dm) risk variables, and integrating ethical considerations into the research design and implementation. the study aims to fill existing gaps in knowledge about tdcs effects on blood glucose regulation and diabetic risk factors by conducting more robust research methodologies the effects of tdcs on addictive behavior and cerebral glucose metabolism in problematic online gamers were examined in a single-blinded rct. over a 4-weekperiod, participants received 12 sessions of either active or sham tdcs to the dorsolateral prefrontal cortex. in the active group, glucose metabolism was enhanced in certain brain regions, showing decreased addiction severity in both groups. as a result of these findings, it appears that prefrontal tdcs is capable of controlling gaming behaviors and enhancing cerebral glucose metabolism

Eligibility criteria:
inclusion criteria: * both male \& female * age 18-30 years exclusion criteria: * pregnancy * lactating mothers * skin irritation and allergies * brain tumor or shunt * brain metallic implants * epileptic disease * gi disorder and endocrine disorder * drug abuse * history of medications any hormonal therapy

Keywords: tdcs glucose uptake healthy young
dysrhythmias during general anesthesia in children

Conditions: Arrhythmias, Cardiac

Summary: to describe the types and incidence of cardiac dysrhythmias that occur under anesthesia in the present anesthesia environment.

it is unclear what the current state of anesthesia associated dysrhythmias is in the pediatric population. this was last investigated retrospectively in 1992 when the predominant volatile agent used for inhalation induction was halothane. sevoflurane was approved by the food and drug administration in 1995. since that time, sevoflurane has displaced halothane as the agent of choice for inhalation induction and has relegated halothane to be used in a narrow niche which primarily involves patients with very specific congenital heart diseases. it has been described that halothane has a larger proarrhythmic effect than sevoflurane for ventricular dysrhythmias. with the transition from the halothane to the sevoflurane era, a reassessment of the incidence and types of dysrhythmias occurring in non-cardiac pediatric patients is important.

Eligibility criteria:
inclusion criteria: children, while under anesthesia, having 1. circumstances of tachycardia and bradycardia, 2. administration of medications used in the treatment of dysrhythmias, 3. the commentary which includes comment about the heart rhythm or therapy for dysrhythmia, 4. in the quality assurance database for evidence of dysrhythmia exclusion criteria: children with a known pre-operative: 1. prior history of dysrhythmia and/or 2. residual congenital heart disease 3. anti/pro dysrhythmic medications

Keywords: children cardiac arrhythmia general anesthesia
ascitic fluid microbiome in liver cirrhosis

Conditions: Ascitic Fluid, Microbiota; Microbiota; Sequence Analysis; Polymerase Chain Reaction

Summary: ascitic fluid microbiome is going to be investigated in this study by using internal transcripted spacer (its) and 16s ribosomal rna (rrna) polymerase chain reaction (pcr) and sequencing as conventional culture methods are lacking sensitivity regarding diagnosis of spontaneous bacterial peritonitis (sbp). all patients with routinely performed ascitic fluid puncture and underlying liver cirrhosis are included in this study. next generation sequencing (ngs) in ascitic fluid, skin swaps from puncture side and stool samples as well as conventional culture methods are performed to investigate the difference in the microbiome between patients with and without sbp.


Eligibility criteria:
inclusion criteria: * underlying decompensated liver cirrhosis * routinely performed ascitic fluid puncture * informed consent exclusion criteria: -
primary lesion treatment for bone metastases

Conditions: Bone Metastases

Summary: this study will carry out a prospective cohort study to study the effect of different primary leison treatment modes on disease control, quality of life, economic cost and survival period of patients with bone metastases from breast cancer and lung cancer by giving radiotherapy or palliative surgery or not giving local treatment for the primary lesion in patients with bone metastases from breast cancer or lung cancer


Eligibility criteria:
inclusion criteria: 1. hr positive breast cancer patients with bone metastasis or non-small-cell lung cancer patients with bone metastasis； 2. aged over 18; 3. ecog：0-1； 4. patients who benefit clinically(cr+pr) after 6 months of treatment. exclusion criteria: 1. the expected life span is less than 3 months; 2. have serious cardiovascular and cerebrovascular diseases, blood coagulation dysfunction, and cannot tolerate surgery; 3. allergies to narcotic drugs; 4. the patient refused the treatment decision of the integrated team.
efficacy of phycocyanin and palmitoylethanolamide for the treatment of chronic prostatitis symptoms

Conditions: Chronic Prostatitis (CP); Chronic Prostatitis With Chronic Pelvic Pain Syndrome; Chronic Prostatitis/ Pelvic Pain Syndrome

Summary: chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) is a bothering condition characterized by pain localized to the pelvic, perineal and/or genital area and lower urinary tract symptoms (luts). phytotherapy, which involves the combination of two or more active compounds, can be used to treat this challenging condition. the aim of this study was to investigate the role of an association of phycocyanin (pc) and palmitoylethanolamide (pea) and selenium (ficoxpea®) in male patients affected by cp/cpps. the main questions the present study aims to answer are: * does ficoxpea® enhance quality of life of cpp/cpps patients? * does it help reducing pain symptoms of cpp/cpps patients? researchers will investigate whether ficoxpea® works to treat cpp/cpps symptoms, so its efficacy, but also its tolerability and adherence to therapy. participants will: * take ficoxpea® once a day for 30 days; * visit the clinic for follow-up visits at 1 and 3 months; * answer validated questionnaires and declare potential adverse events at follow-up visits.


Eligibility criteria:
inclusion criteria: * adult male patients (aged \>18 years) * clinical affection by cp/cpps with symptoms that persisted for ≥ 3 months; * psa values of 4 to 10 ng/ml (at least 2 determinations) * patients must have completed diagnostic work-up, such as multiparametric prostate mri (evidence level 1a according to eau guidelines) with or without subsequent prostate biopsy (according to the diagnostic flow-chart depicted by eau international guidelines). exclusion criteria: * patients with previous diagnosis of prostate cancer * patients who underwent previous low urinary tract surgery * patients who underwent previous intravescical chemotherapy * patients with acute bacterial prostatitis * diagnostic work-up for prostate cancer not completed * patients having antibiotic therapy or specific chronic prostatis treatment (phytotherapy included) or benign prostatic iperplasia treatment (e.g. alpha litics) at the time of the recruitment or finished less than a month before

Keywords: chronic prostatitis chronic pelvic pain syndrome luts pain phycocyanin palmitoylethanolamide ficoxpea® phytotherapy
time restricted eating (treat) pilot study

Conditions: Overweight and Obesity; Pre Diabetes

Summary: the treat pilot is a 3 months open-label pilot study to examine the effect of restricting the duration of eating (time restricted eating) in metabolically unhealthy adults with overweight or obesity. this pilot study will allow the investigator to collect preliminary data for the design of a larger study.

disruption of the circadian rhythm, caused by aging, obesity, shift work, or prolonged daily eating duration into hours normally reserved for sleep, is a recognized risk factor for impaired metabolism and cardiovascular disease risk. mice with disrupted clock gene have dysmetabolism. restricting the eating window in these mice improves their metabolism. data will be collected to examine the feasibility and effect of a lifestyle intervention, aiming to reduce body weight in metabolically unhealthy individuals with overweight and obesity. the treat pilot study employs the use of mobile application to document eating behavior, when, what and how much people eat. in addition, the participants will receive reminders and complete in-person study visits to monitor their eating and sleeping schedule.

Eligibility criteria:
inclusion criteria: * age: 45-73y old * overweight or obesity with bmi ≥25.0 and ≤35.0 kg/m2 * pre-diabetes or diabetes only diet controlled (hba1c \<7%) * elevated blood pressure (bp) 120-129/\<80 mmhg or stage 1 high bp 130-139/80-89 mmhg, with clinical atherosclerotic cardiovascular disease (ascvd) or estimated 10-y cardiovascular disease (cvd) risk \<10% * having ldl cholesterol \<150mg/dl * no known sleep, psychiatric or food intake disorders * in possession of a smart phone * english-speaking * must live in new york city geographical area and not have planned travel schedule interfering with the study exclusion criteria: * history or clinical evidence of condition that affect sleep * significant organ system dysfunction/disease: diabetes, severe pulmonary, kidney or cardiovascular disease, and any evidence of active illness (e.g., fever) * history of seizure disorder * being on medications for diabetes, hypertension or dyslipidemia * previous bariatric surgery * history or current significant psychiatric disorder * use dietary supplements and/or medications known to affect sleep, circadian rhythms or metabolic function * smoking tobacco or using illegal or recreational drugs * consume excessive alcohol (women: \>14 drinks/wk; men: \>21 drinks/wk) * consume large amounts of caffeine daily (\>2 cups of coffee or 8 oz caffeinated drinks per day) * participate in intense exercise (causing heavy breathing and sweating, such as jogging) \>2 d/wk for ≥35 min or moderate exercise (e.g., brisk walking) for \>150 min/wk * shift work * extreme early and late chronotypes * unwilling/unable to provide informed consent

Keywords: time restricted eating overweight obesity metabolic syndrome diabetes treated with metformin and/or diet and hba1c< 7% pre diabetes circadian rhythm
celecoxib efficacy and safety versus diclofenac in acute pain due to cervical sprain related to a traffic accident

Conditions: Pain

Summary: this study will evaluate celecoxib efficacy and safety versus standard doses of diclofenac in acute pain due to cervical injury (due to a sprain) related to a motor vehicle accident

on 21oct2010 study was prematurely terminated due to poor enrollment with subsequent low number of participants. no safety or efficacy issues were involved in the decision to terminate prematurely.

Eligibility criteria:
inclusion criteria: * patients that had suffered a car accident and due to it suffered a cervical sprain exclusion criteria: * recent cervical sprains or other cervical conditions

Keywords: treatment of the acute pain due to cervical sprain celecoxib nsaid diclofenac